Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04261907 |
Recruitment Status :
Terminated
(There were no more subjects enrolled.)
First Posted : February 10, 2020
Last Update Posted : April 4, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
2019-nCoV | Drug: ASC09/ritonavir group Drug: lopinavir/ritonavir group | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection |
Actual Study Start Date : | February 11, 2020 |
Actual Primary Completion Date : | April 13, 2020 |
Actual Study Completion Date : | April 13, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: ASC09/ritonavir group
ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
|
Drug: ASC09/ritonavir group
ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment |
Active Comparator: lopinavir/ritonavir group
Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment
|
Drug: lopinavir/ritonavir group
Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment |
- The incidence of composite adverse outcome [ Time Frame: 14 days ]Defined as(one of them) SPO2≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300mmHg or RR ≥ 30 breaths per.
- Time to recovery [ Time Frame: 14 days ]Clinical recovery was defined as( one of them): sustained (48 hours) alleviation of illness based on symptom scores (fever, cough,diarrhea, myalgia, dyspnea) all being absent and no evidence for progression (newly-presented dyspnea, SpO2 decline ≥3%, respiratory rate ≥ 24 breaths per min without supplemental oxygen). Or undectable viral RNA.
- Rate of no fever [ Time Frame: 14 days ]
- Rate of no cough [ Time Frame: 14 days ]
- Rate of no dyspnea [ Time Frame: 14 days ]
- Rate of no requring supplemental oxygen [ Time Frame: 14 days ]
- Rate of undectable viral RNA [ Time Frame: 14 days ]
- Rate of mechanical ventilation [ Time Frame: 14 days ]
- Rate of ICU admission [ Time Frame: 14 days ]
- Time and rate of laboratory indicators related to disease improvement to return to normal [ Time Frame: 14 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1. Aged between 18 and 75 years, extremes included, male or female
- 2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia, according to the official guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"
- 3. Hospitalised with a new onset respiratory illness (≤7 days since illness onset)
- 4. No family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose
- 5. Must agree not to enroll in another study of an investigational agent prior to completion of Day 30 of study
- 6. Informed Consent Form (ICF) signed voluntarily
Exclusion Criteria:
- 1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress, RR ≥ 30 times / min, or SaO2 / SpO2 ≤ 93% in resting state, or arterial partial pressure of oxygen (PaO2) /concentration of oxygen (FiO2) ≤ 300mmHg (1mmHg = 0.133kpa)
- 2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory failure and mechanical ventilation required, or shock, or combined with other organ failure required ICU monitoring treatment
- 3. Severe liver disease (e.g. Child Pugh score ≥ C, AST > 5 times upper limit)
- 4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets
- 5. Patients with definite contraindications in the label of ritonavir
- 6. Positive serum pregnancy test result for women with childbearing potential at screening
- 7. Using HIV protease inhibitor drugs
- 8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be transferred to another hospital during the study period, patient with multiple basic diseases, etc.)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04261907
China, Zhejiang Province, P.R. China | |
The first affiliated hospital, Zhejiang University School of Medicine | |
Hangzhou, Zhejiang Province, P.R. China, China, 310003 |
Principal Investigator: | Yunqing Qiu, Master | First Affiliated Hospital of Zhejiang University |
Responsible Party: | First Affiliated Hospital of Zhejiang University |
ClinicalTrials.gov Identifier: | NCT04261907 |
Other Study ID Numbers: |
ASC09F-CTP-ZY-01 |
First Posted: | February 10, 2020 Key Record Dates |
Last Update Posted: | April 4, 2022 |
Last Verified: | February 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Coronavirus Infections COVID-19 Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Virus Diseases Respiratory Tract Infections Pneumonia, Viral Pneumonia Lung Diseases Respiratory Tract Diseases Ritonavir |
Lopinavir HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |